# Apollo Hospitals Healthcare Rally: Hospital Growth, ARPOB, Occupancy and 24|7 Profitability > Apollo Hospitals led Nifty gainers as healthcare stocks rallied, but the bigger story lies in the earnings drivers beneath the headline. This analysis examines management commentary on bed expansion, average revenue per occupied bed (ARPOB), occupancy trends, Apollo 24|7’s losses and the pharmacy business restructuring. Explore scenario-based insights into what Apollo’s hospitals, digital healthcare platform and pharmacy operations could truly earn. **Companies**: Apollo Hospitals **Sectors**: Healthcare **Published**: 2026-10-10 **Last Updated**: 2026-10-12 **Source**: https://thesisloop.ai/thesis/apollo-hospitals-healthcare-rally-hospital-growth-arpob-occupancy-and-24-7-67afb700-1db4-468d-99e7-5df71cf993ed ## Score Overview | Company | Management | Business Model | Future Growth | Risk | |---------|-----------|---------------|--------------|------| | Apollo Hospitals | 61/100 | 80/100 | 68/100 | 58/100 | ## Apollo Hospitals (BSE:508869) **Sector**: Healthcare | **Industry**: Hospital ### Management Credibility - **[CATALYST] M&A of Regional Hospital Chains** (NEUTRAL): Continue evaluating bolt-on acquisitions in selected Tier-1 cities and metros. (+1 more commitment) > Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros - Source: Investor PPT · Aug 2026 · p.14 - **[METRIC] Bed Occupancy Rate** (NEUTRAL, NOT_YET_DUE): The commitment concerns the next fiscal year and is not yet due. FY26 Healthcare Services margin increased 22 basis points to 24.4%; established-unit margin was 25.5% in Q4 FY26, up 105 basis points year over year, but neither is the next-year full-period outcome. (1 not yet due, 1 in progress across 2 tracked commitments) > So typically, at a 50% to 55% occupancy level for the entire stock of 1,500 beds is what we would be breaking even. You know in each of the hospitals at that level of occupancy, we expect to break even as we speak. - Source: Concall Transcript · May 2026 · p.12 - **[METRIC] New Bed Maturity Timeline** (NEUTRAL, IN_PROGRESS): Management reaffirmed the approximately ₹150 crore new-unit loss estimate for the coming fiscal year. Q3 reported numbers included approximately ₹15 crore of losses for Pune and Athena, with management noting this reflected three months of costs but only around one to 1.5 months of revenue. The 12-month individual-hospital breakeven objective was not updated. (5 in progress across 5 tracked commitments) > In 2 years, we should be breakeven on 1,300 beds that we are talking about. - Source: Concall Transcript · Feb 2026 · p.17 - **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (NEUTRAL): Management's growth mix aspiration for organic hospital growth is approximately half volume and half case mix and pricing. — target: For 12%–14% organic growth, approximately half from volume and half from case mix and pricing (+1 more commitment) > So we would like to believe that when it is a 12%, 13% organic growth that we look at of 14%, we would like to be half on the volume and the balance half on combination of case mix and pricing. - Source: Concall Transcript · Feb 2026 · p.14 - **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL, IN_PROGRESS): Management reiterated at least 100 basis points of Healthcare Services margin improvement in FY27, specifying that this applies to established units. Established-hospital EBITDA margin was 25.5% in Q4 FY26, but the FY27 target is not yet due. (2 in progress across 2 tracked commitments) > So as we look at our assets and occupancy and even in spite of bringing down the ALOS, we have a headroom for lifting volume and asset utilization by another 8%. We will focus on this as we go forward into the New Year. The second, of course, we have not done any significant cost cutting, which we h - Source: Concall Transcript · Feb 2026 · p.14 - **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (NEUTRAL): Apollo expects to maintain cash-plus-insurance payer mix at approximately 85%, including as it expands outside southern India. — target: Approximately 85% > I think 85% is very maintained. - Source: Concall Transcript · Aug 2026 · p.13 - **[TREND] Massive Capacity Addition Cycle** (NEUTRAL, REVISED): There is progress on commissioning, but the schedule has shifted for some facilities. Pune had 75 beds operationalized during the quarter; Hyderabad, Kolkata and Bangalore were expected to operationalize in Q1 FY27, while Gurugram shifted to Q2 because of environmental-related construction delays of 2–3 months. Management expects roughly half of approximately 1,500 beds to be operationalized in the coming fiscal year, with the balance early FY28. (5 revised across 5 tracked commitments) > Expected commissioning : FY27 ... Gurgaon, NCR ... Census Beds 400 ... Sarjapur-1 ... 150 ... Jubilee Hills (Expansion) ... 80 ... Secunderabad (Expansion) ... 80 ... Malleswaram & Mysore Expansion ... 125 ... Expected commissioning :FY29-FY30 ... Worli, Mumbai ... 500 ... Sarjapur-2 ... 400 ... OMR - Source: Investor PPT · May 2026 · p.17 - **[TREND] Medical Tourism Growing at 20%+ CAGR** (NEUTRAL): Management expects Bangladesh patient volumes to recover, with at least 60% having returned in October, and is exploring additional international markets including Uzbekistan, Africa, Indonesia and Iraq. — target: At least 60% of Bangladesh patients returning > Bangladesh, at least 60% has started coming back in October and we believe that we will mitigate the impact of losing one territory. Also, we are exploring new markets, including the Northern markets in Uzbekistan, etcetera. So those that are surrounding markets, Africa, some with Indonesia, Iraq. - Source: Concall Transcript · Nov 2025 · p.3 - **[TREND] Robotic and Minimally Invasive Surgery** (NEUTRAL): Apollo intends to continue strengthening clinical programs and high-acuity specialties, including oncology, robotics and advanced care pathways. (+1 more commitment) > Alongside capacity expansion, we continue to deepen our clinical leadership through investments in high acuity specialties, oncology, robotics and advanced care pathways. - Source: Concall Transcript · May 2026 · p.4 - Management guided to approximately 28% full-year FY26 platform GMV growth on an adjusted, like-for-like basis, within its stated 25%–30% range. Elsewhere in the call it referenced 30%–35%, but the CFO clarified the expected full-year growth was about 28% after adjusting for GST and the discontinued Amazon channel; IP/OP GMV is excluded. (3 exceeded, 1 missed, 1 revised across 5 tracked commitments) (NEGATIVE, MISSED) > Company expects to achieve INR 250 bn of run rate annualized revenue in Q4 FY27 with EBITDA a range of ~6.5% - 7.0% - Source: Investor PPT · May 2026 · p.36 ### Business Model - **[METRIC] Average Revenue Per Occupied Bed** (POSITIVE, Change: EXPANDING): Hospital revenue grew 14% year on year in Q3 FY26, from ₹27,850 million to ₹31,832 million. The segment remained a major contributor to Apollo’s business, though its share of consolidated revenue was about 49.1% in Q3 FY26, below the 50.6% reported for Q1 FY27 in the later baseline. (2 expanding) > Revenue 31,832 27,850 14%; Healthcare Services Revenue grew by 14% in Q3FY26 (Inpatient Volume grew by 4%; Price of 3% and case mix of 7%). - Source: Investor PPT · Feb 2026 · p.15 - **[METRIC] Bed Occupancy Rate** (POSITIVE, Change: EXPANDING): Hospital revenue increased year over year, led by a 2% increase in inpatient volume and a 7% increase in revenue per inpatient. The latest reported quarter shows expansion, although occupancy was lower than in Q2 FY25. (5 expanding) > Occupancy 70% 65% ... Established Units Volume grew by 11% ... New Units pre-operative expenses / losses in Q1FY27 is ₹ 375 mio. EBITDA margin of established units at 25.9% in Q1FY27. - Source: Investor PPT · Aug 2026 · p.13 - **[METRIC] International Patient Revenue Mix** (NEUTRAL): Apollo reported growing revenue from international patients, up 26% YoY. Management said patients come from 150 countries, but did not disclose the international revenue share, the domestic-versus-international split, or revenue by country. Bangladesh patient volumes had recovered to only 60%–70% of their former peak, so the international business was not fully back to that level. > Revenue from international patients grew by 26% over the same quarter last year. - Source: Concall Transcript · Aug 2026 · p.2 - **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Change: EXPANDING): Higher-complexity specialties were growing faster than the hospital business overall: cardiac, oncology, neurosciences, gastroenterology and orthopaedics recorded 6% volume growth and 14% revenue growth year on year. Management attributed higher revenue per patient largely to a richer mix of cases. This is a favorable shift toward more complex care. (5 expanding) > Cardiac, oncology, neurosciences, gastro and orthopaedics - which remain a key growth engine, delivering a 6% volume and 14% revenue growth on a year-on-year basis. - Source: Concall Transcript · Nov 2025 · p.2 - **[PRINCIPLE] Occupancy Is Primary Margin Lever** (POSITIVE, Change: EXPANDING): Established hospitals' EBITDA margin increased to 25.9% from about 24.2% a year earlier (an increase of approximately 1.7 percentage points). Management attributed the improvement to operating leverage, a richer clinical mix and productivity measures, and said the current level was sustainable. New hospitals remained a drag, with a Rs. 38 crore quarterly EBITDA loss. (1 expanding) > Established hospitals delivered EBITDA margins of 25.9%. This improvement is because of higher operating leverage, clinical case mix and the benefit of ongoing productivity optimization initiatives. - Source: Concall Transcript · Aug 2026 · p.2 - **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (POSITIVE, Change: EXPANDING): Inpatient net revenue from insurance and self-pay together made up 83% in Q1 FY27. Insurance revenue grew 25% and self-pay revenue grew 16% year on year. The transcript does not provide the prior-period combined share, so a share change cannot be calculated. (1 expanding) > Insurance and self-pay continue to form the core of our payer mix, together contributing to 83% of overall inpatient net revenues. Insurance revenues grew by 25%, while self-pay revenues increased by 16% during the quarter. - Source: Concall Transcript · Aug 2026 · p.2 - **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Change: EXPANDING): The presentation shows a broad Indian footprint across metros and non-metros and plans substantial capacity growth: about 3,657 census beds are planned over five years, taking census capacity from 9,483 to approximately 13,100. It does not provide regional revenue shares, so a revenue-based geographic shift cannot be measured. (5 expanding) > Overall Total ... 77 ... Capacity Census Beds 11,147 ... Operational Census Beds 9,857 - Source: Investor PPT · Aug 2026 · p.6 - **[TREND] Medical Tourism Growing at 20%+ CAGR** (POSITIVE, Change: EXPANDING): The Bangladesh patient reduction lowered Healthcare Services revenue by about 1% in Q2 FY26. Management said at least 60% of Bangladesh patient volumes had begun returning by October and described exploring other international markets, including Uzbekistan, Africa, Indonesia and Iraq. The later baseline says Bangladesh volumes had recovered to 60%–70% of their former peak and international-patient revenue was up 26% YoY, supporting a favorable recovery and diversification direction. The transcript gives no international revenue share. (2 expanding) > The reduction in number of patients from Bangladesh has had a 1% impact on Healthcare Services revenue in Q2 FY26. - Source: Concall Transcript · Nov 2025 · p.2 - **[TREND] Robotic and Minimally Invasive Surgery** (POSITIVE, Change: EXPANDING): Apollo reported 16% year-on-year revenue growth in its focus specialties—cardiac, oncology, neurosciences, gastroenterology, orthopedics and transplant—in Q3 FY26. It also cited investment in technologies such as robotics and growth in high-end surgeries. The later baseline specifically reports robotic surgeries increased 85%, indicating further development of this clinical capability, but no comparable Q3 FY26 robotics growth figure is provided. (2 expanding) > The 2 mobile gantries are more or less fully occupied. Sometimes very frequently, we are encountering a wait list - Source: Concall Transcript · Aug 2026 · p.8 - Revenue per inpatient rose 9% year over year, indicating higher average spend per hospital admission. This is consistent with greater pricing and/or case complexity, though the presentation does not separate those effects. (5 expanding across 3 engines) (POSITIVE, Change: EXPANDING) > Revenue 35,670 29,351 22% ... EBIT 6,820 5,610 22% ... margin (%) 19.1% 19.1% ... Healthcare Services Revenue grew by 22% in Q1FY27. Overall Volume grew by 13%. - Source: Investor PPT · Aug 2026 · p.13 ### Future Growth - **[METRIC] Average Revenue Per Occupied Bed** (NEUTRAL, Trend: STEADY): The supplied signal describes Q1 FY27, which is outside this November 2025 presentation. In this document, hospital revenue growth is 9% in Q2 FY26 after 10% in H1 FY26; inpatient-volume growth is about 2% in both periods, while revenue per inpatient is up about 9% in both. The latest quarter therefore shows slower revenue growth, mostly from low patient-volume growth rather than a change in revenue per patient. (1 decelerating, 1 steady, 1 new trend across 3 signals) > Healthcare Services Revenue grew by 9% in Q2FY26 (Inpatient Volume grew by 2% ; Price of and case mix of 7%). ... Average Revenue per In patient grew by 9% to ₹173,318 in Q2FY26 - Source: Investor PPT · Nov 2025 · p.15 - **[METRIC] Bed Occupancy Rate** (POSITIVE, Trend: ACCELERATING): In Q3 FY26, occupancy was 67% and inpatient volume grew 4.5% year on year. The earlier extracted Q1 FY27 data report occupancy of 70% and inpatient growth of 13%, indicating a stronger latest-quarter trajectory. Only two periods are available, so this is an acceleration signal rather than a confirmed long-term pattern. (1 accelerating, 1 reversing, 3 new trend across 5 signals) > Occupancy 70% 65% ... IP Discharges 171,662 151,517 13% ... Overall Volume grew by 13%. - Source: Investor PPT · Aug 2026 · p.13 - **[METRIC] International Patient Revenue Mix** (POSITIVE, Trend: NEW_TREND): International patient revenue increased 26% year on year in Q1 FY27. Bangladesh patient volumes remained at only 60%–70% of their earlier peak, although returning patients were more complex. The transcript does not establish a multi-quarter revenue-growth trajectory. (1 new trend across 1 signal) > Revenue from international patients grew by 26% over the same quarter last year. ... The volume has not reached that level. It is about 60% to 70% of what it used to be. - Source: Concall Transcript · Aug 2026 · p.2 - **[METRIC] New Bed Maturity Timeline** (NEUTRAL): New capacity is beginning to contribute, with Sarjapur already open and Gurgaon scheduled to open during FY27. Gurgaon is expected to contribute more meaningfully from Q4 as patient volumes build; management also cautioned that new-hospital losses may rise during the ramp-up. > Our 180-bed facility in Sarjapur, Bengaluru was operationalized this quarter. Gurgaon remains on track for operationalization in Q3 FY27. - Source: Concall Transcript · Aug 2026 · p.3 - **[PRINCIPLE] Case Mix Determines ARPOB Trajectory** (POSITIVE, Trend: ACCELERATING): Apollo's complex-specialty portfolio continued to grow: cardiac, oncology, neurosciences, gastroenterology and orthopaedics together recorded 6% volume growth and 14% revenue growth in Q2 FY26. The transcript also reports 9% growth in average revenue per patient. With only one comparable period here, this is a new reported data point, not a proven multi-quarter acceleration. (4 new trend, 1 steady across 5 signals) > Total inpatient volumes grew by 13% year-on-year with occupancy at 70%. Average revenue per patient increased by 8% year-on-year to INR 186,630. ... Congo-T volumes increased 15%, while revenues grew 24% year-on-year. These specialties now contribute to 62% of inpatient net revenues - Source: Concall Transcript · Aug 2026 · p.2 - **[TREND] Massive Capacity Addition Cycle** (POSITIVE, Trend: ACCELERATING): Healthcare Services revenue was ₹3,183 crore in Q3 FY26, up 14% year on year, while nine-month revenue was ₹9,287 crore, up 12%. Management sees 12%–14% growth from existing hospitals and expects the new beds to add another 3%–4%. Four new hospitals and the Pune ramp-up are expected to add about 1,500 beds in total, with roughly half operationalized in the coming fiscal year. New-unit losses are estimated at about ₹150 crore for the next year, and management expects the first 750 beds to reach about 40% occupancy in their first year. (1 steady, 1 new trend across 2 signals, 2 leading indicators) > Commissioned 5 new hospitals (~1,000 Census beds) ... Of the total 1,000 Census beds, excluding Gurgaon, 380 beds have been operationalized, with the remaining 620 beds planned to be progressively activated over the next 12–18 months, in line with the phased ramp-up plan. Total Project Cost of ~₹11, - Source: Investor PPT · Aug 2026 · p.15 - **[TREND] Medical Tourism Growing at 20%+ CAGR** (POSITIVE, Trend: NEW_TREND): The transcript quantifies a 1% drag on Healthcare Services revenue from fewer Bangladeshi patients in Q2 FY26, while management said at least 60% of Bangladesh patients had started returning in October and it was exploring additional source markets. It does not report international-patient revenue growth, so the available evidence indicates a recovery in patient flow but not a comparable revenue trend. (1 new trend across 1 signal) > Revenue from international patients grew by 26% over the same quarter last year. The volume growth was broad-based across the network and across all specialties. - Source: Concall Transcript · Aug 2026 · p.2 - **[TREND] Tier-2/3 City Hospital Expansion** (NEUTRAL): Expansion is especially large in the North: Apollo lists 1,658 planned census beds across Gurgaon/NCR, Varanasi, Lucknow, Indore and Delhi projects. This would take Northern Region beds from 1,233 to 2,859 after the listed projects, subject to the construction and opening schedule. > Expansion Plan ... Gurgaon, NCR ... Varanasi, U.P ... Lucknow (Expansion), U.P ... Indore Oncology (Expansion), Madhya Pradesh ... Indore, Madhya Pradesh ... Dwarka, Delhi ... Delhi Cancer Centre & Proton ... Total 2,071 [total beds], 1,658 [census beds]. - Source: Investor PPT · Aug 2026 · p.22 - In Q3 FY26, Healthcare Services revenue grew 14% year on year, supported by 5% volume growth, 4% case-mix improvement and 5% pricing. Inpatient volumes grew 4.5% year on year in Q3, up from 2% in Q2, indicating an improving volume trend. The transcript gives average revenue per patient of ₹180,917 for Q3 versus ₹173,246 in Q2, but does not provide year-on-year growth for this metric. The stated revenue-growth target for existing hospitals is 12%–14%; new beds are expected to add a further 3%–4%. (5 accelerating across 5 signals) (POSITIVE, Trend: ACCELERATING) > Healthcare Services Revenue grew by 22% in Q1FY27 . Overall Volume grew by 13%. (Established Units Volume grew by 11%, price of 4% and Case mix /payor mix of 3%). Average Revenue per In patient grew by 8% to ₹186,630 in Q1FY27. - Source: Investor PPT · Aug 2026 · p.13 ### Risk Assessment - **[METRIC] Bed Occupancy Rate** (POSITIVE, Risk: MODERATE): Occupancy was 69% in Q2 FY26, down from 73% in the prior-year quarter according to the call. The Aug 2026 baseline reports 70% overall occupancy, higher than the Nov 2025 figure, so the risk has eased modestly at the group level. However, the baseline also identifies weaker occupancy in the Western Region (58%), Western established units (56%), and non-metro hospitals (66%), so under-utilisation remains a material issue in parts of the network. (5 easing) > Occupancy 70% ... Non Metros ... 66% ... Bed Occupancy Rate (%) 58% - Source: Investor PPT · Aug 2026 · p.15 - **[METRIC] International Patient Revenue Mix** (NEUTRAL, Risk: MODERATE): The hospital network remains reliant on international patients from Bangladesh for some volume recovery. Management said Bangladesh patient numbers are still well below their former peak, so renewed disruption could weaken demand, even though current patients are more complex cases. [CONCENTRATION] > So, the volume has not reached that level. It is about 60% to 70% of what it used to be. But I would say that we are seeing patients with higher complexity, but for value, it is a little bit higher. But volume-wise, it is about 60% to 70% of what it used to be at its peak. - Source: Concall Transcript · Aug 2026 · p.15 - **[METRIC] New Bed Maturity Timeline** (NEGATIVE, Risk: MODERATE): In the older Q3 FY26 period, management estimated about ₹150 crore of losses from new units in the coming fiscal year; only about ₹15 crore was included in reported results at that point. The Aug 2026 baseline reports ₹37.5 crore of new-unit start-up losses in Q1 FY27, confirming the ramp-up cost is material. Severity is therefore higher in the later period, although the quarterly figure is not directly comparable with the earlier full-year estimate. (3 intensifying, 1 emerging, 1 easing) > Commissioned 5 New Hospitals in the last two quarters. New Units pre – operative expenses / losses in Q1FY27 is ₹ 375 mio. - Source: Investor PPT · Aug 2026 · p.13 - **[PRINCIPLE] Occupancy Is Primary Margin Lever** (NEUTRAL, Risk: MODERATE): Higher hospital margins partly rely on maintaining patient volumes and a richer mix of complex cases. If volumes or the mix of high-acuity procedures weaken, margins could fall from current levels; management said it wants first to sustain established-hospital margins rather than promise a further step-up. [DEMAND] > We have got the benefit of both operating leverage as well as some of the cost control measures that has already been taken. And the other important point is the, we are getting back the IPS volumes as well as you have seen in this quarter. So, it is a good margin. We would like to first sustain the - Source: Concall Transcript · Aug 2026 · p.5 - **[PRINCIPLE] Payor Mix Dictates Revenue Predictability** (NEGATIVE, Risk: MODERATE): The older presentation shows insurance at 45% of inpatient payor mix in H1 FY26. The later baseline reports 46%. This small increase means exposure to insurer reimbursement and payment decisions is slightly greater; no management mitigation or insurer-specific collection data is disclosed. Severity remains MEDIUM. (2 intensifying, 1 stable, 2 insufficient_data) > Inpatient Payor Mix ... Insurance 46% - Source: Investor PPT · Aug 2026 · p.14 - **[TREND] Massive Capacity Addition Cycle** (NEGATIVE, Risk: MODERATE): The Nov 2025 call described a phased schedule for six hospitals: two starting in Q3, two in Q4, and two around Q1, with all census beds expected to be operational by the end of the next fiscal year. The Aug 2026 baseline still reports 620 of 1,000 census beds (excluding Gurgaon) as planned over the next 12–18 months, indicating that a substantial portion remained to be opened. The available figures do not establish whether the schedule slipped, since the earlier plan covered a different set and timing of beds; the risk remains, but direction versus the baseline cannot be reliably measured. (1 insufficient_data, 2 intensifying) > Jubilee's expansion, there is some change in the configuration that we are planning, et cetera, so which is why it is moved to the next year. Secunderabad also, there was some delay because the landlord has taken some time to come back yet on the lease deed. So that is why there has been a delay. - Source: Concall Transcript · Aug 2026 · p.15 - In the older Q2 FY26 presentation, Apollo planned 4,486 total beds, including 3,657 census beds, at an estimated cost of ₹8,294 crore, with about ₹5,800 crore still to spend. The later baseline reports a larger plan of about 4,710 census beds for roughly ₹11,150 crore, with about ₹7,500 crore remaining. The planned spend and remaining funding requirement therefore increased over time; no project-level contingency is disclosed in either assessment. Risk worsened from MEDIUM to HIGH. (5 intensifying, 1 high-severity) (NEGATIVE, Risk: HIGH) > Total Project Cost of ~₹ 11,150 crs with Balance to be spent of ~₹7,500crs. - Source: Investor PPT · Aug 2026 · p.15 ### Scenario Analysis - Apollo Hospitals’ core business is healthcare delivery, which is not directly targeted by the Iran conflict’s energy, shipping, or defence channels. Higher fuel, logistics, and imported medical-supply costs, alongside rupee-driven inflation, could indirectly raise operating expenses, but the evidence does not indicate these are central drivers of its revenue model or competitive position. (NEUTRAL) - AI can support Apollo’s diagnostics, patient triage, call-centre operations and clinical review, potentially helping clinicians and staff process cases more efficiently and direct patients to appropriate care. If these tools lower cost-to-serve or improve referrals into consultations, diagnostics and higher-acuity treatment, Apollo could gain productivity and strengthen its digital channel. However, HealthCo’s growth and Apollo 24|7’s scale are not evidence that AI caused higher revenue or margins, and the digital business still reported a cash loss. Over time, Apollo’s data, care network and distribution could become competitive assets if AI improves outcomes at scale, but it is not positioned as a supplier of the compute infrastructure driving the wider AI capex cycle. (NEUTRAL) > Al-based X-ray/RVG analysis implemented across the entire dental network; pilot initiated in Bangalore with a device partner for foot-health assessment of diabetic patients --- *Generated by [ThesisLoop](https://thesisloop.ai) — AI investment research for Indian equities.* > AI-generated research for informational and educational purposes only — not personalized investment advice, a stock recommendation, or a guarantee of returns. ThesisLoop is not a SEBI-registered investment adviser or research analyst. Do your own diligence and consult a registered professional before making any investment decision.